The absence of dystrophin in Duchenne muscular dystrophy disrupts the dystrophin-
associated glycoprotein complex resulting in skeletal muscle fiber fragility and atrophy …

Duchenne muscular dystrophy (DMD) causes progressive skeletal muscle degeneration
and currently there are few therapeutic options. The identification of new drug targets and …

Abstract Background Histone deacetylase 4 (HDAC4) is a stress‐responsive factor that
mediates multiple cellular responses. As a member of class IIa HDACs, HDAC4 shuttles …

Denervation can activate the catabolic pathway in skeletal muscle and lead to progressive
skeletal muscle atrophy. At present, there is no effective treatment for muscle atrophy …

Background Denervation triggers numerous molecular responses in skeletal muscle,
including the activation of catabolic pathways and oxidative stress, leading to progressive …

Histone deacetylases inhibitors (HDACi) include a growing number of drugs that share the
ability to inhibit the enzymatic activity of some or all the HDACs. Experimental and preclinical …

Skeletal muscle denervation causes muscle atrophy via complex molecular mechanisms
that are not well understood. To better understand these mechanisms, we investigated how …

The overlapping histological and biochemical features underlying the beneficial effect of
deacetylase inhibitors and NO donors in dystrophic muscles suggest an unanticipated …

Skeletal muscle remodelling and contractile dysfunction occur through both acute and
chronic disease processes. These include the accumulation of insoluble aggregates of …

ABSTRACT The Forkhead box O (FoxO) transcription factors are activated, and necessary
for the muscle atrophy, in several pathophysiological conditions, including muscle disuse …